Body mass index associated with glucocorticoid-related weight gain in children with rheumatic disease on high-dose prednisone
Authors' conclusion
Greater BMI was a predictor of severe GC-related obesity for children with rheumatic disease requiring moderate to high-dose prednisone therapy.
Study context
- Population
- Children aged <18 years with rheumatic disease treated with moderate to high-dose prednisone, single Canadian paediatric academic hospital, 2010–2020
- Participants
- 62 children
- Outcome
- GC-related obesity (weight gain >20% and BMI z-score ≥1.88 or >95%ile); predictors eGFR, initial BMI, transaminitis, albumin
- Follow-up
- 12 months
Methodological detailsretrospective chart review, single-centre, binary logistic regression
- Retrospective chart review
- Single-centre
- Binary logistic regression
Main finding
As reported in the abstract
GC-induced obesity by 12 months
Patients meeting criteria for glucocorticoid (GC)-induced obesity
18
29%
Greater pre-GC Body Mass Index (BMI) z-score and risk of GC-induced obesity, OR (95% CI)
OR=2.35, 95%CI=1.39-3.96
p<0.001
Observational data: associations, not effects.
Original publication
Body mass index associated with glucocorticoid-related weight gain in children with rheumatic disease on high-dose prednisone. Clin Exp Rheumatol. Published 14 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →